Vectors Research Management’s VanEck Biotech ETF BBH Stock Holding History

Vectors Research Management’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-16	Closed	-$2K	–	169
2022 Q2	$2K	Hold	16	–	–	﹤0.01%	463
2022 Q1	$3K	Hold	16	–	–	﹤0.01%	423
2021 Q4	$3K	Hold	16	–	–	﹤0.01%	539
2021 Q3	$3K	Buy	+16	New	+$3.36K	﹤0.01%	439

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TIA

Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PGFC

Peapack-Gladstone Financial Corp Bedminster, New Jersey $7.82B AUM 21.06% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Vectors Research Management's BBH Position: Q3 2022 in Review

Vectors Research Management sold out of VanEck Biotech ETF (BBH) in Q3 2022, closing a stake of 16 shares — an estimated $2K sold.

Vectors Research Management first reported a position in BBH in Q3 2021 and held it in 4 quarters. The position peaked at $3K in Q1 2022. 102 funds tracked by Wall St. Rank hold BBH as of Q3 2022.

Vectors Research Management reported no remaining VanEck Biotech ETF position as of Q3 2022 after selling out during the quarter.
Vectors Research Management sold 16 VanEck Biotech ETF shares in Q3 2022, an estimated $2K.
Vectors Research Management first reported a position in VanEck Biotech ETF in Q3 2021 and held it in 4 quarters.
Vectors Research Management's VanEck Biotech ETF position peaked at $3K in Q1 2022.
102 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q3 2022.

Based on Vectors Research Management's 13F filing for Q3 2022, filed 8 Nov 2022.